China SXT Pharmaceuticals Inc (SXTC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, China SXT Pharmaceuticals Inc (SXTC) has a cash flow conversion efficiency ratio of -0.076x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.26 Million) by net assets ($29.71 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see SXTC market cap for the company's overall valuation and market capitalisation.
China SXT Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2016–2026)
This chart illustrates how China SXT Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
China SXT Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of China SXT Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Explore earnings quality score of China SXT Pharmaceuticals Inc to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Fjordland Exploration Inc
V:FEX
|
2.832x |
|
Global Opportunities Trust Ord
LSE:GOT
|
N/A |
|
FNP Technologies SA
PA:MLFNP
|
N/A |
|
Generation Income Properties Inc
NASDAQ:GIPR
|
-0.050x |
|
KOOL2PLAY S.A. ZY -10
F:8Q8
|
-0.070x |
|
XTL Biopharmaceuticals Ltd
F:H2K2
|
N/A |
|
Amati AIM VCT plc
LSE:AMAT
|
-0.004x |
|
Tombador Iron Ltd
AU:TI1
|
-0.062x |
Annual Cash Flow Conversion Efficiency for China SXT Pharmaceuticals Inc (2016–2026)
The table below shows the annual cash flow conversion efficiency of China SXT Pharmaceuticals Inc from 2016 to 2026. View China SXT Pharmaceuticals Inc stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-03-31 | $29.71 Million | $-4.02 Million | -0.135x | +10.97% |
| 2025-03-31 | $15.44 Million | $-2.35 Million | -0.152x | -9.75% |
| 2024-03-31 | $13.93 Million | $-1.93 Million | -0.138x | -2417.87% |
| 2023-03-31 | $14.69 Million | $-80.76K | -0.005x | +96.20% |
| 2022-03-31 | $16.42 Million | $-2.37 Million | -0.145x | -75.27% |
| 2021-03-31 | $15.96 Million | $-1.32 Million | -0.082x | -183.00% |
| 2020-03-31 | $9.40 Million | $934.25K | 0.099x | +361.48% |
| 2019-03-31 | $11.11 Million | $239.19K | 0.022x | -96.32% |
| 2018-03-31 | $3.29 Million | $1.92 Million | 0.584x | +269.46% |
| 2017-03-31 | $1.85 Million | $293.04K | 0.158x | -35.61% |
| 2016-03-31 | $742.77K | $182.47K | 0.246x | -- |
About China SXT Pharmaceuticals Inc
China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers Advanced TCMP, including Directly-Oral-TCMP, and After-Soaking-Oral TCMP; Fine TCMP and Regular TCMP products; and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo,… Read more